Gene injection aims to restore vision in rare blindness
NCT ID NCT06196827
Summary
This early-stage study is testing a new gene therapy, called LX101, for people with a rare inherited eye disease that causes vision loss. The therapy involves a single injection into the eye to deliver a working copy of a faulty gene. Researchers are primarily checking if the treatment is safe and well-tolerated, while also looking for early signs that it might improve vision or light sensitivity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DYSTROPHY ASSOCIATED WITH RPE65 MUTATIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, China
-
Shanghai General Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.